Kornimate/medical-research-clean huggingface dataset:
a electronic system to improve recovery outcomes in patients with drug use disorder

Conditions: Drug Use Disorders; Addiction, Drug

Summary: background: relapse is very common in patients with illicit drug use disorder and contributes to a series of bad consequences that substantially impact patients' physical and social functions. due to the limited existence of effective addiction treatment, the majority of patients with drug use disorder could not access help when needing. mobile health (mhealth) offers a potential solution to improving recovery outcome for patients in community. objective: this paper is a protocol for a randomized controlled trial (rct) of a smart phone application called community-based addiction rehabilitation electronic system (cares) . this interactive system consists of an app for clients and a webpage for service providers, with the aim of teaching clients craving and emergency coping skills and helping service providers to improve work efficiency and effectiveness in community. methods: a randomized controlled trial(rct) will be conducted. sixty drug illicit users who are newly ordered to undergo community rehabilitation will be recruited from the community in shanghai. participants will be 1:1 randomly assigned to receive integrated community rehabilitation by using cares or only receiving routine community rehabilitation for 6 months. corresponding anti-drug social workers will provide service and monitor participants' drug use behavior in accordance with the routine work-flow. outcomes will be assessed at baseline and in the 6th month. the primary study outcome is the performance on illicit drug urine test which will be carried on regularly twice per week during the study period. secondary study outcomes include days that participants interact with anti-drug social workers, and the decrease rate of addiction-related issues severity index.


Eligibility criteria:
inclusion criteria: * (1)illicit drug users who are newly ordered to undergoing community-based rehabilitation will be recruited for the study. * (2)candidates are eligible to participated in if they are aged 20 - 50 years * (3)candidates are eligible to participated in if they are meeting the dsm-v (diagnostic and statistical manual of mental disorders-v) criteria for substance dependence * (4)candidates are eligible to participated in if they are willing to comply with the relevant requirements of the study including using the mobile app * (5)there is no limitation for gender when recruiting participant. exclusion criteria: * (1)illicit drug users who are not newly ordered to undergoing community-based rehabilitation. * (2)candidates' age is less than 20 or older than 50 * (3)candidates does not meet the dsm-v (diagnostic and statistical manual of mental disorders-v) criteria for substance dependence * (4)candidates are not able to use the mobile app

Keywords: mobile health illicit drug use rehabilitation community china
multi-center clinical application of hangzhou criteria in liver transplantation for hepatocellular carcinoma

Conditions: HCC; Liver Transplantation

Summary: liver transplantation is an optimal radical therapy for selected patients with hepatocellular carcinoma. hangzhou criteria could safely and effectively expand milan criteria with expanded population and comparable survival. the purpose of this study was to evaluate the hangzhou criteria in a multi-center cohort.

liver cancer is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related deaths worldwide. among all the liver cancer cases, hepatocellular carcinoma (hcc) constitutes 75-85%. liver transplantation is the most effective treatment for hcc and is in high demand in china. the advent of milan criteria has helped to select the recipients reasonably. however, the organ allocation system driven by the milan criteria seemed to be too strict so that many centers worldwide have expanded the criteria in the aspects of morphological features, histopathology and biomarkers. hangzhou criteria introduce the covariables of histopathologic grading and α-fetoprotein (afp) into the selection of recipients for the first time. based on the multi-center hcc patient cohort undergoing transplantation, this study aims to characterize an ideal candidate selecting system beyond the milan criteria.

Eligibility criteria:
inclusion criteria: * aged ≥18 years and \<=75 with hcc confirmed by histopathology; * undergoing a primary whole or split liver transplant from a deceased donor; exclusion criteria: * incomplete follow-up; * missing essential data for analysis (tumor size, number, differentiation grade, α-fetoprotein (afp)) ; * vascular invasion according to radiological criteria; * perioperative mortality (\<30 days) ;
establishing of an early warming system of premature ovarian insufficiency

Conditions: Primary Ovarian Insufficiency

Summary: premature ovarian insufficiency (poi) is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. the poi guideline development group of eshre recommends the following diagnostic criteria: oligo/ amenorrhea for at least 4 months and an elevated follicle stimulating hormone (fsh) level \>25 miu/ml on two occasion \>4 weeks apart. some clinicians and researchers proposed that poi was a progressive disease and there were three stages of poi: occult poi, biochemical poi, overt poi. however, there is lack of reliable indicators to assess the different stages of poi. the present study is to explore the change of menstruation condition, basal follicle-stimulating hormone, anti-müllerian hormone and antral follicle count during the development of poi, and whether those marks can assess the different stages of poi.


Eligibility criteria:
inclusion criteria: * serum fsh levels ≥10miu/ml/ serum amh levels ≤1.0pg/ml/ afc ≤5, on at least two occasion \>4 weeks apart exclusion criteria: * polycystic ovarian syndrome * other causes of amenorrhea
liposomal cytarabine for central nervous system (cns)-treatment in high-risk acute lymphoblastic leukemia (all)

Conditions: Acute Lymphoblastic Leukemia

Summary: * replacement of intrathecal triple (methotrexate, cytarabine, prednisolone) with intrathecal liposomal cytarabine and prednisolone during maintenance therapy will decrease the cns relapse rate in high-risk all patients. * both acute and long-term toxicity are equal in both treatment arms.

20% of children with all still fails to be cured. the all-2008 protocol is a treatment and research protocol that aims to improve the overall outcome of nordic children and adolescents with all in comparison with the all-2000 protocol and previous nopho protocols. the specific and primary objectives of the randomised study is: 1. to replace intrathecal triple (methotrexate, cytarabine and glucocorticosteroid) by intrathecal liposomal cytarabine and glucocorticosteroid during maintenance therapy in order to decrease the central nervous system relapse rate in high-risk acute lymphoblastic leukemia patients. 2. to evaluate acute and long-term toxicity in both treatment arms.

Eligibility criteria:
inclusion criteria: * high risk acute lymphoblastic leukemia * not eligible for bone marrow transplantation * age 1-18 * written informed consent has been obtained exclusion criteria: * persistent nci grade 3-4 neurotoxicity from previous treatments * bilineage all * leukemia predisposing syndromes (e.g. downs syndrome, ataxia telangiectasia) * previous cancer * known intolerance to nopho all 2008 anticancer agents * sexually active females will use safe contraceptives * previous treatment with intrathecal liposomal cytarabine

Keywords: leukemia central nervous system neurotoxicity liposomal cytarabine children acute lymphoblastic leukemia childhood acute lymphoblastic leukemia intrathecal efficacy safety
performance evaluation of a 3d psir sequence in mri at 1.5t

Conditions: Multiple Sclerosis

Summary: inclusion visit (d0): * verification of inclusion and non-inclusion criteria * information and collection of consent * standard imaging protocol prescribed as part of the usual treatment: sagittal t1 and t2 slices after injection of contrast product (gadolinium), o 3d stir sequence. * 3d psir sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35 minutes).


Eligibility criteria:
inclusion criteria: * patient over 18 years old * to benefit from a medullary exploration planned by mri 1.5t as part of a first evaluation or a re-evaluation of inflammatory involvement of the nevrax * express consent to participate in the study * affiliate or beneficiary of a social security scheme exclusion criteria: * patient benefiting from a legal protection measure * pregnant, parturient or breastfeeding woman * absolute or relative contraindication to mri
pattern of statins use in catalonia

Conditions: Hypercholesteremia

Summary: to describe the new statins prescription pattern in catalonia (getting their first prescription for any statin, or receiving a change in their statin treatment including switching, changing in doses or adding ezetimibe/fibrates) since september 2009.

pattern of statins use in catalonia.

Eligibility criteria:
inclusion criteria * patient with a new prescription of statin patients receiving one or more changes of the statins treatment exclusion criteria * patient with not full information

Keywords: statins pattern of use hypercholesterolemic patients statins
pufa supplementation in premature infants

Conditions: Premature, Extremely Low Birth Weight Infants; Polyunsaturated Fatty Acid Levels

Summary: the purpose of this study is to determine if buccal administration of a concentrated formulation of long-chain polyunsaturated fatty acids (lcpufa) can help to maintain docosahexaenoic acid (dha) levels in extremely low birth weight (elbw) infants.

this will be a multi-center, randomized, placebo controlled, double blind trial. two doses of pufa will be compared to placebo- a "high" dose and a "low" dose. elbw infants will be enrolled into this study.

Eligibility criteria:
inclusion criteria: * a) premature infant born at gestational age less than 34 weeks * b) birth weight less than 1000 grams * c) legally authorized representative is able to provide written informed consent within the first 72 hours of life, prior to the performance of an protocol-specified evaluations or procedures exclusion criteria: * a) infants with known metabolic disorder * b) infants with known congenital gastrointestinal anomaly * c) infants who are deemed to be inappropriate for enrollment per attending neonatologist

Keywords: neonatal prematurity infant, extremely low birth weight fatty acids, polyunsaturated
addition of pre-wound closure povidone iodine wash versus direct wound closure effect on surgical site infections

Conditions: Surgical Site Infection; Surgical Wound Infection

Summary: a randomized controlled trail to to assess the efficacy of povidone-iodine wash before wound closure in preventing surgical site infections.

surgical site infections are post-operative infections of the incision or organ or space that was included in the surgical field. incisional surgical site infections (ssis) are a growing healthcare challenge. currently, up to 10% of surgical procedures may be complicated by an ssi \[3\]. not only do ssis lead to worse patient outcomes, but they also account for a large proportion of healthcare expenditure. in the united kingdom alone, ssis are estimated to cost the national health service 1 billion pounds annually. the problem is further compounded in low- and middle-income countries (lmics) where the prevalence of antibiotic-resistant infections is increasing, and national healthcare budgets are strained. in fact, ssis are estimated to account for additional costs of up to $30,000 in lmics. the global crisis of drug-resistant bacteria has further highlighted the need for more effective perioperative preventive strategies to minimize healthcare-associated resistant infections. optimal surgical antisepsis is critical in reducing the incidence of ssis, and therefore in reducing the use of postoperative antibiotics. recently, there has been a renewed interest in using povidone-iodine (pvi) intraoperative wound irrigation to achieve this goal. the choice of pvi is especially suitable for lmics where the availability of chlorhexidine preparations may be limited by scarce resources. a possible adjunctive role of pre-wound closure pvi irrigation in reducing incisional ssis is still unclear. a meta-analysis by lópez-cano et al. analyzed data of 7,601 patients and found a reduction in overall ssi rate. however, the heterogeneity and uncertain quality of most studies limited the synthesis of conclusive evidence. the possible benefits of irrigating the surface of an open incision include local antimicrobial effect, physical removal of debris and dilution of contamination. recent guidelines have all emphasized the lack of sufficient evidence on intraoperative use of pvi. the investigators aim to conduct a randomized controlled trial in ain shams university hospitals to compare the effect of adding pvi wash prior to skin closure to direct wound closure on reducing the rates of ssis.

Eligibility criteria:
inclusion criteria: * adult patients (≥ 18 years old) * open and minimally invasive surgeries * emergency (any unplanned admission) and elective (planned admission) surgical procedures * clean, clean-contaminated, contaminated, dirty wounds * inclusion surgery list according to current procedural terminology (cpt) national healthcare safety network (nhsn) operative procedure code mapping exclusion criteria: * povidone-iodine allergy * surgeries for infected wounds. * exclusion surgery list according to current procedural terminology (cpt) national healthcare safety network (nhsn) operative procedure code mapping.
rx-5902 treatment of subjects with triple negative breast cancer

Conditions: Solid Tumor; Triple Negative Breast Cancer

Summary: the purpose of this phase 2 portion of the study is to use the dose and schedule of rx-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.

in this dose-finding, open-label, single-agent study of rx-5902, subjects will be treated for up to 6 cycles of therapy. rx-5902 will be administered orally daily for 3 weeks followed by 1 week of rest in each cycle. all subjects will be followed for at least 30 days after the last dose of study agent for safety.

Eligibility criteria:
inclusion criteria: * male and female who are 18 yrs or older * histologically confirmed triple negative breast cancer that are refractory, intolerant, or ineligible to receive approved standard therapies * measurable or evaluable disease per response evaluation criteria in solid tumors (recist) * life expectancy of at least 3 months * able to swallow capsules * provide written informed consent exclusion criteria: * primary brain tumor or active brain metastasis * not recovered to less than or equal to grade 1 toxicities (except grade 2 alopecia or neuropathy) associated with previous cancer therapies * any other cancer treatments within 2 weeks of planned study treatment * history of any medical or psychiatric condition or addictive disorder, or lab abnormality that in the opinion of the investigator, may increase risks or may interfere with study participation or interpretation of study results * history of clinically significant gi bleed, intestinal obstruction, or gi perforation within 6 months of study dose * uncontrolled diabetes * history of long qt syndrome or clinically significant cardiac arrhythmias (except stable atrial fibrillation) * myocardial infarction within 6 months of study dose * active infection requiring iv antibiotics within 2 weeks of study dose * history of hepatitis b, c, or hiv * use of potent inhibitor or inducer of cyp3a4/3a5 within 14 days of planned study treatment or expected requirement for use of such a drug during study * use of a potent inhibitor or inducer of drug transporters or conjugating enzymes within 14 days prior to planned study treatment or expected requirement for use of such a drug during study * receiving other investigational agents or not yet completed 30 days since completion of an investigational study * pregnant, planning a pregnancy, or breast feeding * male or female not willing to use adequate contraceptive precautions during the study period. females must either be surgically sterile, post-menopausal for 12 months, or use a contraceptive approved by sponsor. * unwilling or unable to provide written informed consent, comply with study requirements, or be available for follow-up assessments

Keywords: metastatic rexahn phase 1 triple negative breast cancer phase 2 relapsed
clinical evaluation of fenugreek seed extract, a nutraceutical in patients with type- 2 diabetes

Conditions: Type-2 Diabetes Mellitus

Summary: in the proposed study, hydroalcoholic fenugreek seed extract will used add-on to the existing therapy in patients with type-2 diabetes. the efficacy and safety of the extract will be evaluated using standard methodology.

trigonella foenum-graecum, commonly known as fenugreek, is a plant that has been extensively used as a source of antidiabetic compounds, from its seeds, leaves and extracts in different systems of medicine in asia. fenugreek is traditionally used in india, especially in the ayurvedic and unani systems. preliminary animal and human studies suggest possible hypoglycemic and anti-hyperlipidemic properties of fenugreek seed powder taken orally. in a randomized placebo controlled study conducted by gupta et al showed that two month treatment with the hydro-alcoholic extract of fenugreek seeds improved glycemic control in 12 non-insulin dependent diabetes mellitus patients. in addition, there was improvement in insulin sensitivity and plasma lipid profile. fenugreek extract was also well tolerated in diabetic patients. in the proposed study, hydroalcoholic fenugreek seed extract will used add-on to the existing therapy in patients with type-2 diabetes. the efficacy and safety of the extract will be evaluated using standard methodology.

Eligibility criteria:
inclusion criteria: * patients suffering from type-2 diabetes of less than 10 years duration * patients with hba1c \>7.0% * patients with fasting plasma glucose not exceeding 180 mg/dl * patients with negative urine sugar * patients who are on oral hypoglycaemic agents containing either metformin or sulfonylurea or both * there should not be any change their in anti-diabetic treatment for at least one month exclusion criteria: * patients with diabetes other than type-2 diabetes mellitus * patients with evidence of renal disease (s. creatinine \> 1.5mg/dl) * patients with evidence of liver disease (ast/alt \>3 times of normal * pregnant and lactating mothers and women intending pregnancy * patients who participated in any other clinical trial within the last 30 days * patients with history of any hemoglobinopathy * history of intolerance or hypersensitivity to fenugreek

Keywords: fenugreek seed extract hba1c blood glucose
high-flow nasal cannula oxygenation decrease hypoxia in sedated gastrointestinal endoscopes in obesity

Conditions: Hypoxia; Gastric Cancer; Esophagus Cancer; Polyp of Colon; Colon Cancer

Summary: hypoxia is the most common adverse event during gastrointestinal endoscopes sedated with propofol and sufentanil, especially in obese people. in the present study, high-flow nasal cannula oxygenation will be utilized in order to reduce the incidence of hypoxia among obesity.


Eligibility criteria:
inclusion criteria: * patients undergoing gastrointestinal endoscopes * age≥18 years old and ≤70 years old * patients or family members signed informed consent form * asa classification i-ii * bmi≥ 28kg/m² exclusion criteria: * coagulation disorders or a tendency of nose bleeding; * an episode/exacerbation of congestive heart failure (chf) that requires a change in medication, diet or hospitalization from any cause in the last 6 months; * severe aortic stenosis or mitral stenosis; * cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (cabg), valve replacement surgery) in the last 6 months; * acute myocardial infarction in the last 6 months; * acute arrhythmia (including any tachycardia - or bradycardia) with the fluid of hemodynamics instability; * diagnosed chronic obstructive pulmonary disease or current other acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy); * increased intracranial pressure; * asa classification ⅲ-ⅳ ; * mouth, nose, or throat infection; * liver and kidney disease * fever, defined as core body temperature \> 37.5℃; * pregnancy, breastfeeding or positive pregnancy test; * emergency procedure; * patients or family members refused to participate * mental disorders and people without civil capacity

Keywords: hypoxia gastrointestinal endoscopes high-flow nasal cannula oxygenation
methods of assessment of adenoid size

Conditions: Adenoid Hypertrophy

Summary: chronic nasal obstruction due to adenoid hypertrophy is among the most common health problems affecting children, and adenoidectomy is one of the most common surgical procedures performed in this age group because of difficulties associated with the use of the objective methods (such as nasopharyngeal endoscopy) in young children, the development of a reliable scale based on the child's symptoms to properly evaluate the need for surgical intervention would be of great value for clinicians. when adenoidectomy is being considered, the diagnosis and documentation of adenoidal hypertrophy become an important issue. numerous modalities have been used for this task, including trans oral digital palpation and trans oral mirror examination; however, these methods are quite impractical with uncooperative younger children

assessment of the nasopharynx and adenoids by fibreoptic examination bears the advantage of direct visualization of the postnasal space. in addition, previous studies have demonstrated that adenoid size, as determined by rhinoscopy, was well correlated with clinical symptoms such as nasal obstruction and snoring. the aim of this study was to compare the effectiveness of lateral neck radiography and video rhinoscopy in assessing adenoid size . assessment of the reproducability of these modalities to associated symptoms and, thus, the severity of the disease.

Eligibility criteria:
inclusion criteria: * children aged 3 _ 14 years old * clinical diagnosis of adenoid hypertrophy in the form of chronic oral respiration , nasal disorders and snoring * recurrent otitis media exclusion criteria: 1. patients diagnosed with nasal obstruction due to anatomic malformation ( congenital, choanal atresia, stenosis or septal deviation ) 2. age less than 3 years or more than 14 years 3. patient with craniofacial malformation and down syndrome